Fermenta Biotech Limited (FERMENTA) has successfully listed its equity shares on the National Stock Exchange of India Limited (NSE). Effective August 4, 2026, the company’s shares are now admitted to dealings on the NSE under the symbol FERMENTA and ISIN INE225B01021. This milestone marks a significant step in Fermenta’s 75-year journey, providing access to shareholders and market participants across both major Indian stock exchanges.

Dual Listing Advantage

The dual listing on the NSE and the Bombay Stock Exchange (BSE) under the code 506414 is expected to increase accessibility and participation for a wider community of investors. Prashant Nagre, Managing Director of Fermenta Biotech, emphasized that this listing enables broader participation, improved visibility, and more efficient price discovery.

Company’s Growth and Commitment

Founded in 1951 and listed on the BSE since 1977, Fermenta Biotech has grown from its pharmaceutical and biotechnology foundations into a globally recognized manufacturer. The company serves customers in more than 60 countries with its portfolio of premium nutritional ingredients, green chemistry, APIs, and customized food premixes. Nagre highlighted that the NSE listing reflects the company’s growth, expanding global customer base, and widening investor interest.

The listing ceremony was held at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex, attended by representatives from NSE, Fermenta’s Board, and senior leadership team. This event commemorates Fermenta’s milestone year, celebrating 75 years of the company and nearly five decades as a publicly listed enterprise.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fermenta Biotech Limited

Fermenta Biotech Limited. Here’s a quick read on where the business and the stock stand today.

Fermenta gains 81.6% over three months and trades near its 52-week highs. Revenue grows at only 0.0% and profits at 0.0% CAGR. In effect, the business treads water. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI hits 77, a level that signals the stock runs hot. Notably, buyers drove volume on 18 recent sessions — though at these levels, some profit-taking is normal. The stock rises 81.6% in three months. Yet revenue grows at only 0.0% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Fermenta Biotech Limited.